Introduction
Lorlatinib is a targeted therapy drug used primarily in the treatment of non-small cell lung cancer (NSCLC) that is positive for anaplastic lymphoma kinase (ALK) gene rearrangements. It is an oral medication that inhibits ALK and ROS1 tyrosine kinases, which are involved in the growth and spread of cancer cells.
Uses
Lorlatinib is indicated for:
- Treatment of metastatic non-small cell lung cancer (NSCLC) with ALK gene rearrangements, including cases that have progressed after treatment with other ALK inhibitors.
- Treatment of NSCLC with ROS1 gene rearrangements in patients who have previously been treated with other ROS1 inhibitors or have not received any prior treatment.
| Brand Name | Lorlatinib |
|---|---|
| Type | |
| Weight | |
| Generic | Lorlatinib |
| Manufacturer | |
| Available in | English বাংলা |
Mechanism of Action
Lorlatinib works as a tyrosine kinase inhibitor by binding to and inhibiting the activity of ALK and ROS1 kinases. These kinases are involved in cell signaling pathways that drive the growth and proliferation of cancer cells. By blocking these pathways, lorlatinib helps to slow or stop the growth of cancer cells.
How Long Does It Take to Work?
The time it takes for lorlatinib to show therapeutic effects can vary. Some patients may begin to see improvements within a few weeks, but significant clinical responses might take 1 to 3 months of treatment. Regular monitoring by a healthcare provider is necessary to assess the drug's efficacy.
Absorption
Lorlatinib is well absorbed from the gastrointestinal tract, with peak plasma concentrations typically reached within 1 to 2 hours after oral administration. The bioavailability of lorlatinib is high, and its absorption is not significantly affected by food intake.
Route of Elimination
Lorlatinib is primarily metabolized in the liver by cytochrome P450 enzymes. The drug and its metabolites are excreted mainly through the feces, with a smaller amount eliminated in the urine. The majority of the drug is cleared from the body in the form of metabolites.
Dosage
The recommended dose is 100 mg Lorlatinib taken orally once daily. Treatment with Lorlatinib is recommended as long as the patient is deriving clinical benefit from therapy without unacceptable toxicity. If a dose of Lorlatinib is missed, then it should be taken as soon as the patient remembers unless it is less than 4 hours before the next dose, in which case the patient should not take the missed dose. Patients should not take 2 doses at the same time to make up for a missed dose.Dosing interruption or dose reduction may be required based on individual safety and tolerability. Lorlatinib dose reduction levels are summarized below:
- First dose reduction: 75 mg taken orally once daily.
- Second dose reduction: 50 mg taken orally once daily.
The recommended dose of lorlatinib is 100 mg taken orally once daily. Dosage adjustments may be necessary based on tolerability and the presence of side effects. It is important to follow the prescribed dosage and consult with a healthcare provider before making any changes.
Administration
Lorlatinib should be taken orally with or without food, at the same time each day. The tablets should be swallowed whole and not crushed or chewed. If a dose is missed, it should be taken as soon as possible, but if it is almost time for the next dose, skip the missed dose and resume the regular dosing schedule.
Side Effects
Common side effects of lorlatinib include:
- Fatigue.
- Nausea and vomiting.
- Diarrhea.
- Edema (swelling).
- Changes in appetite or weight.
- Pneumonitis or interstitial lung disease.
- Severe liver problems.
- Neurological effects, such as dizziness or confusion.
Toxicity
Toxicity from lorlatinib can manifest as severe side effects, including significant liver enzyme abnormalities or severe neurological symptoms. In the case of overdose, supportive care and symptom management are necessary, and immediate consultation with a healthcare provider is recommended.
Precautions
Precautions include:
- Regular monitoring of liver function and blood cell counts.
- Assessing for signs of pulmonary symptoms or neurological disturbances.
- Adjusting the dose based on tolerance and side effects.
Interaction
Lorlatinib can interact with other medications, especially those that affect liver enzymes, such as CYP3A4 inhibitors or inducers. It is important to inform healthcare providers of all medications being taken to avoid potential interactions and adjust treatment as needed.
Disease Interaction
Lorlatinib should be used with caution in patients with:
- Pre-existing liver conditions or elevated liver enzymes.
- History of severe pulmonary issues.
- Neurological disorders.
Drug Interaction
Lorlatinib may interact with drugs that are strong CYP3A4 inhibitors or inducers. Examples include:
- Strong CYP3A4 inhibitors: ketoconazole, itraconazole.
- Strong CYP3A4 inducers: rifampin, phenytoin.
Food Interactions
Food intake does not significantly affect the absorption of lorlatinib. The drug can be taken with or without food. However, it is advisable to maintain a consistent routine to ensure stable drug levels and effectiveness.
Pregnancy Use
Lorlatinib is classified as a Category X drug by the FDA, indicating that it is contraindicated during pregnancy due to potential harm to the fetus. Women of childbearing potential should use effective contraception while taking lorlatinib and consult their healthcare provider regarding pregnancy planning.
Lactation Use
It is unknown whether lorlatinib is excreted in breast milk. Given the potential for serious adverse effects in a nursing infant, it is recommended that breastfeeding be discontinued during treatment with lorlatinib.
Acute Overdose
In the event of an acute overdose, symptoms may include severe side effects such as liver toxicity or neurological disturbances. Supportive care and symptom management are essential, and prompt medical consultation is necessary.
Contraindication
Lorlatinib is contraindicated in patients who are pregnant or have a known hypersensitivity to the drug or its components. It should also be used with caution in individuals with severe hepatic impairment or those with severe pulmonary or neurological conditions.
Use Direction
Lorlatinib should be taken exactly as prescribed, with a consistent daily dosing schedule. It is crucial to follow the healthcare provider’s instructions regarding dosage and administration and to report any side effects or concerns promptly.
Storage Conditions
Lorlatinib should be stored at room temperature, between 20°C to 25°C (68°F to 77°F). Keep the medication in its original container, tightly closed, and protected from moisture and light. Keep out of reach of children.
Volume of Distribution
The volume of distribution for lorlatinib is approximately 1000 L, indicating extensive tissue distribution beyond the plasma compartment.
Half Life
The terminal half-life of lorlatinib is approximately 24 to 30 hours. This extended half-life allows for once-daily dosing and helps maintain steady-state plasma concentrations over time.
Clearance
Lorlatinib is primarily cleared through hepatic metabolism, with its clearance influenced by liver function and the presence of other medications. The drug's clearance is generally consistent with its extensive distribution and metabolism.
See in details version Lorlatinib also Lorlatinib in bangla
